Genentech

Disparities in care still remain for women's health, especially in neurology. At the American Academy of Neurology Annual Meeting (#AANAM) this week in San Diego, we're coming together to elevate the voices and experiences of women in the field of neurology by diving deep into strategies to reduce health disparities and eliminate disadvantages in the future care of women. Hear from Dr. Stephanie Buxhoeveden, Chief Scientific Officer of the Accelerated Cure Project, at our panel, EmpowerHer: Brain Health in Women Reception on April 6 at 6:00pm PT to learn more about the importance of collaboration across clinical, research, and lived experiences to prioritize and preserve brain health in women. Register here: http://spr.ly/6046Fgyiq

Improving health access and outcomes starts with meeting local communities where they are. We recently joined McKesson, Kenvue, and The Leukemia & Lymphoma Society at the Western Navajo Fair to support local health education efforts focused on cancer, diabetes and nutrition. We can’t do this work alone. Coming together to ensure communities have the knowledge and support they need to lead healthy, thriving lives is essential for this meaningful work. Take a look at how this work came to life: https://lnkd.in/gwzNkhZD

We’re at #ADPD2025 presenting new data from our #neuroscience portfolio highlighting our research to address the unmet needs of people living with Alzheimer’s. By 2050, #Alzheimers is expected to impact 150 million people globally and we’re committed to improving their lives and outcomes. Learn more about our Alzheimer’s research: https://lnkd.in/gtX4_udE

Two Scientists Walk Into a Bar returns for season 6 this month! This season, we’re revisiting exciting topics to show how fast science is evolving. Catch up on some of our favorite moments from previous seasons and get ready for more groundbreaking discoveries! http://spr.ly/6041FwGjP

In this special teaser episode, hosts Maria Wilson and Danielle Mandikian share an exciting preview into season 6 of our podcast, Two Scientists Walk Into a Bar. This season, they’ll dive into some of the biggest challenges in medicine, from addressing unmet needs in lung disease to exploring how cell therapy unlocks treatments for previously undruggable diseases. Tune in now for a sneak peek! http://spr.ly/6048FTKNa

Our podcast, Two Scientists Walk Into a Bar is returning for season 6! Join hosts Maria Wilson and Danielle Mandikian as they sit down with experts tackling unmet needs in areas like obesity and antibiotic resistance, and across different stages of drug development. From cutting-edge cell therapies to AI-driven breakthroughs, they’ll take a deep dive into the future of medicine. Don’t miss out—catch up on past episodes and subscribe to tune into season 6! http://spr.ly/60410hBIH

Neurofilament light chain (NfL), a structural protein found in neurons, is a well known biomarker for neurodegeneration, but its role in disease progression is not well understood. In a recent study in Cell Reports, our scientists observed that removing NfL delayed disease onset and reduced inflammation in preclinical models of amyotrophic lateral sclerosis (ALS). These findings suggest that NfL plays a direct role in disease pathology and could serve as a potential therapeutic target for neurodegenerative diseases. Learn more: http://spr.ly/60410Wsa1 #Neuroscience #ALS #Neurodegeneration #Biomarkers This image, captured by the gRED Neuroscience Department, shows brain tissue where NfL was injected into the left hippocampus. The dark staining shows activated microglia (brain immune cells) in the region where NfL was injected.

In a recent article, Charles Fuchs, SVP and Global Head of Oncology & Hematology Drug Development at Genentech, discussed how we are addressing a need for new more effective therapies for HR+ breast cancer with targeted therapies like novel PI3K inhibitors and next-gen selective estrogen receptor degraders (SERDs). These innovations are changing the treatment landscape and improving outcomes for patients. Read the full article here: http://spr.ly/60460mibp

As Senior Vice President of Early Clinical Development, Lilli Petruzzelli brings together experts across multiple therapeutic areas to accelerate the journey from scientific discoveries to real-world therapies. Her leadership drives a forward-thinking approach that leverages advanced research and AI-driven insights to streamline drug development, making innovative therapies available to patients faster. Learn more about Lilli and how her commitment to innovation is shaping the future of early clinical development. http://spr.ly/604503Pvt

In breast cancer, more than 40% of HR+ cases carry PIK3CA mutations, leading to hyperactive PI3K signaling that promotes tumor growth. Advances in genetic testing—like next-generation sequencing—make it easier to identify patients with these mutations, paving the way for physicians to provide more personalized care. Learn more from Katherine Ansley, Clinical Associate Professor of Hematology and Oncology at Wake Forest University School of Medicine: http://spr.ly/6049055y7